CDMRP Tuberous Sclerosis Complex Research Program: Clinical Translational Research Award

The Clinical Translational Research Award supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC.

Projects supported by this award mechanism may include, but not limited to:

• Understanding and treating the features of TSC-Associated Neuropsychiatric Disorders and reducing their impact, including pharmacological and behavioral interventions.
• Strategies for preventing and eradicating tumors and cysts associated with TSC (e.g., angiomyolipomas, Subependymal Giant Cell Astrocytomas, Lymphangiolomyomatosis [LAM], etc.), including gaining a deeper mechanistic understanding of tumor microenvironment, TSC signaling and mTOR-independent pathways.
• Preventing epilepsy, improving treatment, and mitigating neurodevelopmental outcomes associated with TSC-related seizures.
• Developing, assessing, and testing emerging technologies including imaging and molecular therapeutic strategies, such as gene therapy, to improve outcomes in TSC

Projects that are exploratory and/or strictly animal research will not be considered for funding.

It is expected that 2 awards will be granted. 

Funding: $1,000,000 total ($150,000 addition for partnering PI) 
Duration: 3 years

Research Authority due date:  3.6.24

Pre application (required) due date: 12.6.24

Full application due date: 1.8.24